Retatrutide

What is Retatrutide?

An investigational triple-agonist peptide that has shown substantial weight loss and metabolic improvements in phase 2 trials, though it remains unapproved.

This profile is educational. It organizes publicly discussed research context for Retatrutide and related naming aliases — it is not a treatment guide.

Proposed mechanism

Simultaneously activates GLP-1, GIP, and glucagon receptors, potentially amplifying effects on appetite, energy expenditure, and glycemic control beyond single- or dual-agonist approaches.

Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.

Current research notes

Human evidence grade: Moderate human evidence

Preclinical evidence grade: Moderate human evidence

GL3RT (retatrutide, LY3437943) is among the most discussed investigational obesity agents. Phase 2 data published in NEJM (2023) reported mean weight reductions approaching 24% at higher doses over 48 weeks, alongside improvements in blood pressure, lipids, and liver fat. Researchers have studied its triple-receptor profile as a rationale for superior efficacy versus GLP-1-only agents. Human evidence remains limited to controlled trials; long-term cardiovascular and safety outcomes are still being characterized in ongoing phase 3 programs. Regulatory status is investigational worldwide.

Key uncertainties

• Long-term durability beyond 48 weeks
• Comparative effectiveness vs approved dual agonists
• Optimal patient selection undefined

Research areas being studied

• Obesity
• Type 2 diabetes
• MASLD/NAFLD
• Cardiometabolic risk

Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.

Safety & side-effect notes

Reported or discussed adverse effects

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Increased heart rate

Additional risks & considerations

• Gastrointestinal tolerability
• Investigational safety profile incomplete
• Heart rate increases reported in trials

Regulatory status

Investigational

Not FDA approved; in phase 3 development for obesity and related metabolic conditions.

Regulatory framing here is educational and can lag policy changes. Check official sources for current status.

Frequently asked questions

References & sources

• Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — NEJM. Evidence type: human.
• Multiple authors (2022). Retatrutide pharmacology and receptor binding profile — Diabetes Obes Metab. Evidence type: in_vitro.